[go: up one dir, main page]

PL2214666T3 - Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny - Google Patents

Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny

Info

Publication number
PL2214666T3
PL2214666T3 PL08836256T PL08836256T PL2214666T3 PL 2214666 T3 PL2214666 T3 PL 2214666T3 PL 08836256 T PL08836256 T PL 08836256T PL 08836256 T PL08836256 T PL 08836256T PL 2214666 T3 PL2214666 T3 PL 2214666T3
Authority
PL
Poland
Prior art keywords
amyloid
microgliosis
neurotoxicity
reducing
deposition
Prior art date
Application number
PL08836256T
Other languages
English (en)
Inventor
Michael J Mullan
Daniel Paris
Robert A Ivey Iii
Original Assignee
Alzheimers Inst Of America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheimers Inst Of America Inc filed Critical Alzheimers Inst Of America Inc
Publication of PL2214666T3 publication Critical patent/PL2214666T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL08836256T 2007-10-05 2008-10-03 Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny PL2214666T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97795307P 2007-10-05 2007-10-05
US4610908P 2008-04-18 2008-04-18
EP08836256.1A EP2214666B1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
PCT/US2008/078786 WO2009046323A1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Publications (1)

Publication Number Publication Date
PL2214666T3 true PL2214666T3 (pl) 2014-06-30

Family

ID=40523447

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08836256T PL2214666T3 (pl) 2007-10-05 2008-10-03 Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny

Country Status (16)

Country Link
US (2) US8236346B2 (pl)
EP (1) EP2214666B1 (pl)
JP (1) JP5411145B2 (pl)
KR (1) KR101417200B1 (pl)
CN (1) CN101883564B (pl)
AU (1) AU2008308519B2 (pl)
BR (1) BRPI0817516A2 (pl)
CA (1) CA2701620C (pl)
DK (1) DK2214666T3 (pl)
ES (1) ES2449594T3 (pl)
MX (1) MX2010003669A (pl)
NZ (1) NZ584729A (pl)
PL (1) PL2214666T3 (pl)
RU (1) RU2490014C2 (pl)
TW (1) TWI500422B (pl)
WO (1) WO2009046323A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
ES2043719T3 (es) 1987-06-12 1994-01-01 American Cyanamid Co Administracion de farmacos por via percutanea.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate
EP0317780B1 (en) 1987-11-25 1992-05-20 American Cyanamid Company Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2718105B2 (ja) 1988-10-27 1998-02-25 藤沢薬品工業株式会社 （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶
US5053419A (en) * 1989-03-31 1991-10-01 The Children's Medical Center Corporation Treatment of AIDS dementia, myelopathy and blindness
JPH0381262A (ja) 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5258393A (en) * 1990-02-21 1993-11-02 Fujisawa Pharmaceutical Co., Ltd. Use of a dihydropyridine compound for improving inner ear microcirculation
EP0557290A1 (en) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1993005770A1 (en) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE69427981T2 (de) * 1993-06-30 2001-11-29 Fujisawa Pharmaceutical Co., Ltd. Verkapselter arzneistoff
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
EP1085863A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Cross-reference to related applications
EP1085890A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Novel sodium channel drugs and uses
AU753486B2 (en) 1998-07-10 2002-10-17 Novartis Ag Method of treatment and pharmaceutical composition
WO2001064250A1 (fr) 2000-03-03 2001-09-07 Fujisawa Pharmaceutical Co., Ltd. Remedes contre une nevrose concomitante a une tumeur maligne et le virus azoor ou des maladies analogues associees
WO2001076598A1 (fr) 2000-04-11 2001-10-18 Sankyo Company, Limited Compositions pharmaceutiques stabilisees contenant des bloqueurs des canaux calcium
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
DE60127410T2 (de) * 2000-07-27 2007-12-13 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
WO2002049650A2 (de) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
MXPA03005393A (es) * 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
ES2275007T3 (es) 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
WO2003024457A1 (fr) * 2001-09-11 2003-03-27 Asahi Kasei Kabushiki Kaisha Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PE20040468A1 (es) 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
CA2485081C (en) 2002-05-17 2013-01-08 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
BR0317747A (pt) 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
ES2334029T3 (es) * 2003-05-15 2010-03-04 Roskamp Research Llc Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer

Also Published As

Publication number Publication date
US20090092667A1 (en) 2009-04-09
KR101417200B1 (ko) 2014-08-01
EP2214666A1 (en) 2010-08-11
RU2490014C2 (ru) 2013-08-20
JP2010540661A (ja) 2010-12-24
US8236347B2 (en) 2012-08-07
JP5411145B2 (ja) 2014-02-12
ES2449594T3 (es) 2014-03-20
TW200920364A (en) 2009-05-16
WO2009046323A1 (en) 2009-04-09
BRPI0817516A2 (pt) 2015-06-16
US8236346B2 (en) 2012-08-07
AU2008308519B2 (en) 2014-09-11
DK2214666T3 (da) 2014-01-27
EP2214666B1 (en) 2013-12-11
US20100183711A1 (en) 2010-07-22
RU2010117634A (ru) 2011-11-10
MX2010003669A (es) 2010-11-25
CN101883564A (zh) 2010-11-10
CN101883564B (zh) 2013-10-16
CA2701620A1 (en) 2009-04-09
CA2701620C (en) 2014-12-09
AU2008308519A2 (en) 2010-04-29
EP2214666A4 (en) 2010-12-08
KR20100067683A (ko) 2010-06-21
TWI500422B (zh) 2015-09-21
AU2008308519A1 (en) 2009-04-09
NZ584729A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
EP2141393A4 (en) VALVE MANUFACTURING METHOD AND VALVE
IL238437A (en) Method for Preparation of 3-Aryl-5-Trifluoromethyl-5,4-Dihydro-Isoxazoles
PL2520605T3 (pl) Sposób wytwarzania biobójczej poliguanidyny i biobójcza poliguanidyna
ZA200908428B (en) Method for the production of a component, and component
GB0707096D0 (en) Method
EP2053146A4 (en) METHOD FOR MANUFACTURING ELECTROFORMED MOLD, ELECTROFORMED MOLD, AND METHOD FOR MANUFACTURING ELECTROFORMED PARTS
EP2171169A4 (en) METHOD
GB0714442D0 (en) Method
EP2316633A4 (en) ART RESIN PRODUCT AND METHOD FOR THE PRODUCTION THEREOF
ZA201100511B (en) Manufacturing method for absorptive article.
EG25901A (en) Watering device, method for manufacturing said device, and means therefore
GB0719592D0 (en) Compound, use and method
EP2261262A4 (en) METHOD FOR PRODUCING POLYURONATE
GB0703366D0 (en) Method
ZA201000399B (en) Spinning method
PL2151328T3 (pl) Folia, sposób jej wytwarzania i zastosowanie
TWI367821B (en) Mold and method for manufacturing the same
GB0710321D0 (en) Method
GB0708960D0 (en) Method
EP2305638A4 (en) ASYMMETRIC AZIN COMPOUND AND METHOD OF MANUFACTURING THEREOF
EP2368705A4 (en) PROCESS FOR PREPARING A BAG AND BAG
TWI372517B (en) Equalizer and method for configuring the equalizer
GB0705321D0 (en) Method
PL2214666T3 (pl) Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny
EP2412163A4 (en) MULTIMEDIA DISTRIBUTION NETWORK, COMPONENTS AND METHODS RELATING THERETO